Payment overview · 2025
General Payments
$412.40
17 reported records · 10 companies
Healthcare provider profile · identity verified
Mousa Matar, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · RIVERSIDE, CA · NPI 1992116982
Verified facts
What the public records show
CMS Open Payments records show Mousa Matar, M.D. received $412.40 in general payments during 2025 across 17 reported records.
AstraZeneca Pharmaceuticals LP accounted for 40.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $165.12 | 40.0% | 6 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $47.02 | 11.4% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $35.02 | 8.5% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $28.54 | 6.9% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $27.43 | 6.7% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $25.56 | 6.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $24.98 | 6.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.40 | 5.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.44 | 4.7% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.89 | 4.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $412.40 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $132.71 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $101.26 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $68.85 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $47.02 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $28.54 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $28.54 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $27.43 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $25.56 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $24.98 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.40 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $18.89 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.13 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
35 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 652 | 225 |
| Amlodipine Besylate | Amlodipine Besylate | 336 | 114 |
| Levothyroxine Sodium | Levothyroxine Sodium | 332 | 93 |
| Eliquis | Apixaban | 313 | 74 |
| Losartan Potassium | Losartan Potassium | 266 | 79 |
| Furosemide | Furosemide | 251 | 88 |
| Lisinopril | Lisinopril | 247 | 91 |
| Gabapentin | Gabapentin | 227 | 76 |
| Metformin Hcl | Metformin Hcl | 203 | 74 |
| Pantoprazole Sodium | Pantoprazole Sodium | 191 | 72 |
| Metoprolol Tartrate | Metoprolol Tartrate | 171 | 66 |
| Omeprazole | Omeprazole | 168 | 67 |
| Tamsulosin Hcl | Tamsulosin Hcl | 146 | 55 |
| Hydrochlorothiazide | Hydrochlorothiazide | 145 | 44 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 130 | 48 |
| Zolpidem Tartrate | Zolpidem Tartrate | 128 | 21 |
| Metoprolol Succinate | Metoprolol Succinate | 119 | 45 |
| Potassium Chloride | Potassium Chloride | 118 | 39 |
| Clopidogrel | Clopidogrel Bisulfate | 116 | 43 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 114 | 49 |
| Famotidine | Famotidine | 109 | 45 |
| Simvastatin | Simvastatin | 105 | 36 |
| Carvedilol | Carvedilol | 103 | 38 |
| Trazodone Hcl | Trazodone Hcl | 100 | 42 |
| Alendronate Sodium | Alendronate Sodium | 86 | 28 |
| Atenolol | Atenolol | 83 | 29 |
| Ezetimibe | Ezetimibe | 78 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 77 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 73 | 31 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 69 | 21 |
| Sodium Chloride | 0.9 % Sodium Chloride | 69 | 23 |
| Alprazolam | Alprazolam | 65 | 20 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 63 | 20 |
| Amiodarone Hcl | Amiodarone Hcl | 62 | 21 |
| Humalog Kwikpen U-100 | Insulin Lispro | 61 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 61 | 29 |
| Ibuprofen | Ibuprofen | 59 | 17 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 58 | 18 |
| Montelukast Sodium | Montelukast Sodium | 58 | 22 |
| Allopurinol | Allopurinol | 57 | 20 |
| Benazepril Hcl | Benazepril Hcl | 57 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 57 | 17 |
| Enoxaparin Sodium | Enoxaparin Sodium | 55 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 54 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 53 | 17 |
| Meloxicam | Meloxicam | 52 | 16 |
| Glipizide | Glipizide | 51 | 16 |
| Azithromycin | Azithromycin | 49 | 37 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 49 | 21 |
| Pioglitazone Hcl | Pioglitazone Hcl | 48 | 15 |
| Sertraline Hcl | Sertraline Hcl | 47 | 16 |
| Memantine Hcl | Memantine Hcl | 46 | 15 |
| Donepezil Hcl | Donepezil Hcl | 45 | 19 |
| Lovastatin | Lovastatin | 45 | 15 |
| Spironolactone | Spironolactone | 44 | 16 |
| Buspirone Hcl | Buspirone Hcl | 42 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 42 | 14 |
| Entresto | Sacubitril/Valsartan | 41 | suppressed |
| Xarelto | Rivaroxaban | 40 | 12 |
| Cefdinir | Cefdinir | 38 | 31 |
| Fenofibrate | Fenofibrate Nanocrystallized | 37 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 36 | 24 |
| Warfarin Sodium | Warfarin Sodium | 36 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 35 | 11 |
| Synthroid | Levothyroxine Sodium | 35 | 12 |
| Glimepiride | Glimepiride | 33 | 12 |
| Januvia | Sitagliptin Phosphate | 33 | suppressed |
| Mirtazapine | Mirtazapine | 33 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 32 | 16 |
| Midodrine Hcl | Midodrine Hcl | 32 | suppressed |
| Lorazepam | Lorazepam | 30 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 30 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 29 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 28 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 28 | 15 |
| Metformin Hcl Er | Metformin Hcl | 28 | suppressed |
| Nifedipine Er | Nifedipine | 28 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 28 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Jardiance | Empagliflozin | 27 | suppressed |
| Lactulose | Lactulose | 27 | 12 |
| Levetiracetam | Levetiracetam | 27 | 11 |
| Celecoxib | Celecoxib | 26 | suppressed |
| Cephalexin | Cephalexin | 26 | 23 |
| Valacyclovir | Valacyclovir Hcl | 26 | suppressed |
| Daptomycin | Daptomycin | 25 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 25 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Lidocaine | Lidocaine | 25 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Sucralfate | Sucralfate | 24 | 14 |
| Tramadol Hcl | Tramadol Hcl | 24 | 15 |
| Vancomycin Hcl | Vancomycin Hcl | 24 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 23 | suppressed |
| Folic Acid | Folic Acid | 23 | suppressed |
| Dexamethasone | Dexamethasone | 22 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 22 | suppressed |
| Glipizide Er | Glipizide | 22 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Methocarbamol | Methocarbamol | 22 | 15 |
| Prednisone | Prednisone | 22 | 18 |
| Baclofen | Baclofen | 21 | 12 |
| Divalproex Sodium | Divalproex Sodium | 21 | suppressed |
| Temazepam | Temazepam | 21 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Eszopiclone | Eszopiclone | 19 | suppressed |
| Gemfibrozil | Gemfibrozil | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | 16 |
| Pregabalin | Pregabalin | 19 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 15 |
| Minoxidil | Minoxidil | 18 | suppressed |
| Modafinil | Modafinil | 18 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Xifaxan | Rifaximin | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Loperamide | Loperamide Hcl | 17 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | suppressed |
| Clobazam | Clobazam | 16 | suppressed |
| Ertapenem | Ertapenem Sodium | 16 | suppressed |
| Felodipine Er | Felodipine | 16 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 12 |
| Lacosamide | Lacosamide | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | 11 |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 13 |
| Colchicine | Colchicine | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 13 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 12 |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 13 | suppressed |
| Scopolamine | Scopolamine | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 11 | suppressed |
| Arformoterol Tartrate | Arformoterol Tartrate | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Humulin N Kwikpen | Insulin Nph Human Isophane | 11 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
| Voriconazole | Voriconazole | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $412.40 · 17 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, Cologuard Collection Kit, FARXIGA, GVOKE HYPOPEN, Kerendia, OTEZLA, REPATHA, UBRELVY, Veozah, Wegovy, YUPELRI | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error